 Herbal-based composition for treating acute and chronic myeloid leukemia |
| 1. A method of treating either CD33+ acute myeloid leukemia or CD33+ chronic myeloid leukemia by ... |
|
| Cosmetic compositions with agglomerated substrates |
| OF PREFERRED EMBODIMENTS Below, the invention is explained in more detail by means of examples. A... |
|
| Emulsifier-free finely disperse systems of the oil-in-water and water-in-oil type |
| The invention claimed is: 1. Pickering emulsions, which are finely disperse water-in-oil or oil-in-... |
|
| Isolates of pythium species which are antagonistic to Pythium ultimum |
| What is claimed is: 1. A biologically pure culture of Pythium isolate N2 having the identifying ... |
|
| Bacterial substance and pharmaceutical composition thereof |
| AND PREFERRED EMBODIMENT The term "treatment" used herein is intended to cover all the controls of ... |
|
| Compounds, compositions, and methods for controlling biofilms |
| This invention relates to compounds, compositions, and methods for controlling biofilms. "C... |
|
| Benzylidenenorcamphor derivatives |
| What is claimed is: 1. A method for screening the skin or hair from the sun comprising applying to ... |
|
| Cosmetic compositions comprising a film-forming polymer a citric acid ester and a plasticizing agent |
| We claim: 1. A cosmetic composition for forming a film on skin, eyelashes, eyebrows, hair, or nails ... |
|
|
Identification of drug candidates modulating factor VII-mediated intracellular signaling
| Details |
Inventors: Kongsbak, Lars; Bergenhem, Niels; Petersen, Lars Christian; Thastrup, Ole; Foster, Don;
Assignee: Novo Nordisk A/S (Bagsvaerd, DK)
Primary Examiner: Weber; Jon P.
Assistant Examiner:
Attorney, Agent or Firm: Green, Esq.; Reza
The present invention provides methods for identifying candidate drugs that modulate factor VIIa-mediated intracellular signaling by measuring the effects of such drugs on the activation of the mitogen-activated protein kinase (MAP kinase) signaling pathway. |
|
DETAILED DESCRIPTION OF THE INVENTION The present invention relates to the use of FVII or FVIIa or another TF agonist for the manufacture of a pharmaceutical composition for inducing or enhancing activation of the MAPK signalling pathway in a patient, in particular wherein phosphorylation of MAPK/Erk1/2 leads to activation of transcription factor Elk1.
The present invention also relates to the use of FVII, FVIIa or another TF agonist for the manufacture of a pharmaceutical composition for enhancing FVIIa-induced activation of the MAPK signalling pathway in a patient.
In a further aspect the present invention relates to the use of FVII, FVIIa or another TF agonist for the manufacture of a pharmaceutical composition for inducing or enhancing activation of transcription factor Elk1.
In a still further aspect the present invention relates to the use of FVIIai or another TF antagonist for the manufacture of a pharmaceutical composition for inhibiting or preventing activation of the MAPK signalling pathway in a patient.
In a further aspect the present invention relates to the use of FVIIai or another TF antagonist for the manufacture of a pharmaceutical composition for inhibiting or preventing activation of transcription factor Elk1 in a patient.
In a still further aspect the present invention relates to use of FVIIai or another TF antagonist for the manufacture of a pharmaceutical composition for inhibition or prevention of FVIIa-induced activation of the MAPK signalling pathway in a patient.
In an embodiment of the present invention it relates to the use of FVIIa or another TF agonist for the manufacture of a pharmaceutical composition for the treatment of re-endothelization, co-lateral revascularization in ischemia/reperfusion in myocardial infarction diabetic microangiopathy.
In another embodiment of the present invention it relates to the use of FVIIai or another TF antagonist for the manufacture of a pharmaceutical composition for the treatment of restenosis, cancer.
In a further aspect the present invention concerns a method for inducing or enhancing activation of the MAPK signalling pathway in a patient, which comprises administering an effective amount of FVII or FVIIa or another TF agonist to said patient
|
| Related patents |
|
|
Method for providing enteric coating on solid dosage forms and aqueous compositions therefor
OF THE PREFERRED EMBODIMENTS Extensive investigations have been undertaken by the inventors with an object to solve the above described problems in the prior art ...
|
|
|
Method for preparing film coated pharmaceutical preparations and method for improving properties thereof
What is claimed is: 1. A method for providing white colored film coated pharmaceutical preparations, said method comprising the steps of providing pharmaceutical ...
|
|
|
Delayed, sustained-release pharmaceutical preparation
OF THE PREFERRED EMBODIMENTS The preferred delayed, sustained-release pharmaceutical preparation of the present invention is a water soluble core drug surrounded by a ...
|
|
|
Delayed, sustained-release diltiazem pharmaceutical preparation
OF THE PREFERRED EMBODIMENTS The preferred delayed, sustained-release pharmaceutical preparation of the present invention is a water soluble core drug surrounded by a ...
|
|
|
Extended release, film-coated tablet of astemizole and pseudoephedrine
We claim: 1. A four-part tablet comprising: (a) an extended release matrix core comprising pseudoephedrine hydrochloride as the active ingredient, a hydrophilic polymer ...
|
|
|
Pseudoephedrine hydrochloride extended-release tablets
OF THE PREFERRED EMBODIMENTS In a preferred embodiment of the present invention a combination comprising at least one active ingredient together with ...
|
|
|
Orally administrable nifedipine pellet and process for the preparation thereof
OF THE EMBODIMENTS A. A Fast-Release Type of Nifedipine Pellet The fast-release type of nifedipine pellet described in this embodiment comprises: (1) a particulate core,...
|
|
|
Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
Ethylcellulose, which is a cellulose ether that is formed by the reaction of ethyl chloride with alkaline cellulose, is completely insoluble in water and ...
|
|
|
Tea catechins as cancer specific proliferation inhibitors
The invention described herein encompasses a method of treating cancer or solid tumors comprising the administration of a therapeutically effective amount of catechins, ...
|
|
|
Mucorales fungi for use in preparation of foodstuffs
OF THE INVENTION The fermentation process of the first aspect is suitably conducted in a fermenter vessel adapted for containing the aqueous liquid, such as a vat, and ...
|
|
|
Weight Loss and Supplements 
